Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

Study acronym: ARQ-MA-000260
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Aug 10, 2026 to Sep 10, 2026
    • Eligibility criteria expanded, about 25 words
    • Study site revised
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study investigates the efficacy of topical roflumilast foam in patients with HS.
Trial Details
NCT Number NCT07689188
Lead Sponsor Harrison Dermatology
Conditions
(from sponsor)		 Hidradenitis Suppurativa (HS)
Related terms Hidradenitis Suppurativa
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov